NZ515711A - Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation - Google Patents

Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation

Info

Publication number
NZ515711A
NZ515711A NZ515711A NZ51571100A NZ515711A NZ 515711 A NZ515711 A NZ 515711A NZ 515711 A NZ515711 A NZ 515711A NZ 51571100 A NZ51571100 A NZ 51571100A NZ 515711 A NZ515711 A NZ 515711A
Authority
NZ
New Zealand
Prior art keywords
necrocis
cox
tnf
antagonists
tumors
Prior art date
Application number
NZ515711A
Inventor
J Keane
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Publication of NZ515711A publication Critical patent/NZ515711A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

The present invention provides combinations of a tumor necrosis factor antagonizing agent and a cyclooxygenase-2 inhibiting agent for treating inflammatory disease in a mammal.
NZ515711A 1999-06-24 2000-06-26 Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation NZ515711A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14123899P 1999-06-24 1999-06-24
PCT/US2000/016292 WO2001000229A1 (en) 1999-06-24 2000-06-26 Combination of tumors necrocis factor (tnf) antagonists and cox-2 inhibitors for the treatment of inflammation

Publications (1)

Publication Number Publication Date
NZ515711A true NZ515711A (en) 2004-01-30

Family

ID=22494803

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ515711A NZ515711A (en) 1999-06-24 2000-06-26 Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation

Country Status (7)

Country Link
EP (1) EP1189628A1 (en)
JP (1) JP2003503360A (en)
AU (1) AU5873000A (en)
CA (1) CA2369145A1 (en)
NZ (1) NZ515711A (en)
WO (1) WO2001000229A1 (en)
ZA (1) ZA200110349B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
CA2817619A1 (en) 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
KR100949528B1 (en) 2001-09-19 2010-03-25 니코메드 게엠베하 Combination of a nsaid and a pde-4 inhibitor
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
ES2213485B1 (en) 2003-02-13 2005-12-16 Almirall Prodesfarma, S.A. DERIVATIVES OF 2-FENILPIRAN-4-ONA.
ES2214130B1 (en) * 2003-02-13 2005-12-01 Almirall Prodesfarma, S.A. 2-3'-BIPIRIDINES.
WO2004104217A2 (en) * 2003-05-08 2004-12-02 Wyeth Protein kinase c zeta as a drug target for arthritis and other inflammatory diseases
WO2005004806A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Combination therapy for treating chronic inflammatory diseases
TW201705980A (en) 2004-04-09 2017-02-16 艾伯維生物技術有限責任公司 Multiple-variable dose regimen for treating TNF[alpha]-related disorders
US20060046961A1 (en) * 2004-09-02 2006-03-02 Mckay William F Controlled and directed local delivery of anti-inflammatory compositions
CN102961746B (en) 2005-05-16 2016-06-15 艾伯维生物技术有限公司 The purposes of TNF α inhibitor for treatment of erosive polyarthritis
WO2008063213A2 (en) 2006-04-10 2008-05-29 Abbott Biotechnology Ltd. Uses and compositions for treatment of psoriatic arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
EP2010214A4 (en) 2006-04-10 2010-06-16 Abbott Biotech Ltd Uses and compositions for treatment of rheumatoid arthritis
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
DE102007035063A1 (en) 2007-07-26 2009-01-29 Spiegelberg (Gmbh & Co.) Kg Process for the preparation of an antimicrobial plastic product
US11331294B2 (en) 2007-09-26 2022-05-17 Indiana University Research And Technology Corporation Benzoquinone derivative E3330 in combination with chemotherapeutic agents for the treatment of bladder cancer
WO2009042544A1 (en) 2007-09-26 2009-04-02 Indiana University Research And Technology Corporation Quinone derivatives, pharmaceutical compositions, and uses thereof
US20140128398A1 (en) 2011-06-03 2014-05-08 Indiana University Research And Technology Corporation Compounds, compositions and methods for treating oxidative dna damage disorders
CA3201564A1 (en) 2020-12-09 2022-06-16 Jung Min Yoo Anti-ox40l antibody, anti-ox40l/anti-tnfalpha bispecific antibody, and uses thereof
KR102445482B1 (en) * 2021-09-17 2022-09-20 오가노이드사이언스 주식회사 Pharmaceutical formulation comprising organoid and anti-inflammatory agent for preventing or treating inflammatory bowel disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5672347A (en) * 1984-07-05 1997-09-30 Genentech, Inc. Tumor necrosis factor antagonists and their use
US5605690A (en) * 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5731343A (en) * 1995-02-24 1998-03-24 The Scripps Research Institute Method of use of radicicol for treatment of immunopathological disorders
DK1479385T3 (en) * 1996-10-15 2008-08-04 Searle Llc Use of cyclooxygenase-2 inhibitors for the treatment and prevention of neoplasia
US6887893B1 (en) * 1997-12-24 2005-05-03 Sankyo Company, Limited Methods and compositions for treatment and prevention of tumors, tumor-related disorders and cachexia
AU3596500A (en) * 1999-02-19 2000-09-04 Pozen, Inc. Formulation of 5-ht agonists with cox-2 inhibitors

Also Published As

Publication number Publication date
ZA200110349B (en) 2002-12-18
JP2003503360A (en) 2003-01-28
WO2001000229A1 (en) 2001-01-04
EP1189628A1 (en) 2002-03-27
AU5873000A (en) 2001-01-31
CA2369145A1 (en) 2001-01-04

Similar Documents

Publication Publication Date Title
NZ515711A (en) Combination of tumors necrocis factor (TNF) antagonists and COX-2 inhibitors for the treatment of inflammation
ATE283700T1 (en) THERAPEUTIC USE OF A HEDGEHOG SIGNAL TRANSMISSION PATHWAY INHIBITOR
AU2210400A (en) Method of using a cyclooxygenase-2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
PT912558E (en) SUBSTITUTED INDAZOLE DERIVATIVES AND THEIR USE AS TYPE IV PHOSPHODIESTERASE (PDE) INHIBITORS AND TUMOR NECROSIS (TNF) FACTOR INHIBITORS
TW200507833A (en) Treatment and prevention of otic disorders with Cox-2 inhibitors alone or in combination with otic agents
NZ333399A (en) Cyclooxygenase-2 inhibitors (COX-2) for the prevention and treatment of tumors, cachexia and tumor-metastasis
IL128642A0 (en) Indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and the production of tumor necrosis factor (tnf)
BG108214A (en) Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
EA200300953A1 (en) THERAPEUTIC COMBINATIONS FOR USE IN CARDIOVASCULAR AND INFLAMMATORY DISEASES
HUP0203968A3 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
IL152083A0 (en) Substituted indazole derivatives and their use as inhibitors of phosphodiesterase (pde) type iv and of the production of tumor necrosis factor (tnf)
EP1515982A4 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
WO2002098444A3 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
CA2380904A1 (en) Nsaid and efgr kinase inhibitor containing composition for the treatment or inhibition of colonic polyps and colorectal cancer
HK1050860A1 (en) Nordihydroguaiaretic derivatives for use in treatment of tumors
PL349149A1 (en) Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia
AU3111700A (en) Methods and compositions for treating inflammatory diseases utilizing inhibitorsof tumor necrosis factor activity
TNSN04015A1 (en) Combination therapy for the treatment of cancer
PL329855A1 (en) Inhibitors of s-cd23 formation and tumour necrosis factor release
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
MXPA02010759A (en) (2-oxindol-3-ylidenyl)acetic acid derivatives and their use as protein kinase inhibitors.
AU2001282990A1 (en) Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
WO2002032429A3 (en) Use of inhibitors of progesterone receptor for treating cancer
HK1079116A1 (en) Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and radiotherapy
PL370459A1 (en) Substituted urea retinoid agonists ii

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)